Jinarc Indications/Uses

Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease (see Pharmacology: Pharmacodynamics under Actions).
Recommendations: 1. Jianarc is used in patients ages 18-55 years with eGFR >25 mL/min/1.73 m² GFR indexed for age compatible with disease progression as following: 1. Age <40 years: any GFR; 2. Age 40-44 years: < 90 mL/min/1.73 m²; 3. Age 45-49 years: < 75 mL/min/1.73 m²; 4. Age 50-55 years: < 60 mL/min/1.73 m².
2. Recommendation 1 + any one of fast progression as following: 1. GFR decline > 3.0 mL/min/1.73 m² per year over a period of ≥ 4 years; 2. Kidney size > 16.5 cm; 3. Truncating PKD1 mutation or family history (renal insufficiency with ADPKD before 60 years and PROPKD score > 6; 4. MRI result of renal cyst comply with Mayo classification 1D or 1E.
Discontinued when patients approach end stage renal disease or any contraindication.